Edwards Lifesciences Corporation  (EW)
Other Ticker:  
Price: $80.7600 $1.21 1.521%
Day's High: $81.02 Week Perf: -0.39 %
Day's Low: $ 79.37 30 Day Perf: 4.1 %
Volume (M): 2,759 52 Wk High: $ 131.10
Volume (M$): $ 222,825 52 Wk Avg: $89.46
Open: $79.55 52 Wk Low: $67.13

 Market Capitalization (Millions $) 50,372
 Shares Outstanding (Millions) 624
 Employees 15,700
 Revenues (TTM) (Millions $) 5,382
 Net Income (TTM) (Millions $) 1,522
 Cash Flow (TTM) (Millions $) -95
 Capital Exp. (TTM) (Millions $) 265

Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is also a global leader in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting.

Cardiovascular disease is the number-one cause of death in the world, and is the top disease in terms of health care spending in nearly every country. Cardiovascular disease is progressive in that it tends to worsen over time and often affects an individual's entire circulatory system.

The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular.

Patients undergoing surgical treatment for cardiovascular disease may be treated using a variety of Edwards Lifesciences' products and technologies. For example, an individual with a heart valve disorder may have a faulty valve. A clinician may elect to remove the valve and replace it with one of Edwards Lifesciences' bioprosthetic surgical tissue heart valves, surgically re-shape and repair the faulty valve with an Edwards Lifesciences annuloplasty ring, or deploy an Edwards Lifesciences transcatheter valve via a minimally invasive catheter-based system. If a patient undergoes open-heart surgery, Edwards Lifesciences' Cardiac Surgery Systems products may be used while the patient's heart and lung functions are being bypassed, or used during minimally invasive valve surgery. Virtually all high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function monitored by Edwards Lifesciences' Critical Care products. If the circulatory problems are in the limbs rather than in the heart, the patient's procedure may involve some of Edwards Lifesciences' Vascular products, which include various types of balloon-tipped catheters that are used to remove blood clots from diseased blood vessels.

Edwards Lifesciences' principal executive offices are located at One Edwards Way, Irvine, California 92614. The telephone number at that address is (949) 250-2500.


The medical device industry is highly competitive. Edwards Lifesciences competes with many companies, ranging from small start-up enterprises to companies that are larger with broader product offerings than Edwards Lifesciences. Furthermore, new product development and technological change characterize the areas in which Edwards Lifesciences competes. The present or future products of Edwards Lifesciences could be rendered obsolete or uneconomical as a result of technological advances by one or more of Edwards Lifesciences' present or future competitors or by other therapies, including drug therapies. Edwards Lifesciences must continue to develop and acquire new products and technologies to remain competitive in the cardiovascular medical device industry. Edwards Lifesciences believes that it competes primarily on the basis of clinical superiority and innovative features that enhance patient benefit, product reliability, performance, customer and sales support, and cost-effectiveness.

The cardiovascular segment of the medical device industry is dynamic and subject to significant change due to cost-of-care considerations, regulatory reform, industry and customer consolidation, and evolving patient needs. The ability to provide products and technologies that demonstrate value and improve clinical outcomes is becoming increasingly important for medical device manufacturers.

Edwards Lifesciences believes that it is globally one of the leading competitors in each of its major product lines. The Company's products and technologies face substantial competition from a number of companies including divisions of companies much larger than Edwards Lifesciences and smaller companies that compete in specific product lines or certain geographies. In Surgical and Transcatheter Heart Valve therapies, the Company's primary competitors include St. Jude Medical, Inc., Medtronic, Inc. and Sorin Group. In Critical Care, Edwards Lifesciences competes primarily with a variety of companies in specific product lines including ICU Medical, Inc., PULSION Medical Systems AG and LiDCO Group PLC.

   Company Address: One Edwards Way Irvine 92614 CA
   Company Phone Number: 250-2500   Stock Exchange / Ticker: NYSE EW
   EW is expected to report next financial results on April 27, 2023.

Customers Net Income grew by EW's Customers Net Profit Margin grew to

10.37 %

3.04 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABT        1.07% 
BSX        0.56% 
MDT        1.38% 
• View Complete Report

Shoe Carnival Inc

Demanding fiscal period for SCVL during the November to January 28 2023 period

For the most recent fiscal period SCVL earnings per share dropped by -30.46 % of $0.80 per share compare to $1.15 a year ago and income faded by -32.5 % from $1.18 per share from the preceding reporting period.

Sales crumbled by -20.822 % to $290.78 millions from $367.25 millions in the corresponding reporting period a year ago and sequentially Sales deteriorated by -14.893 % from $341.66 millions.

Generation Asia I Acquisition Limited

Sales have tumbled at Generation Asia I Acquisition Limited in the October to December 31 2022 span

For the fourth quarter of 2022 Generation Asia I Acquisition Limited income per share dived by -65.25 % of $0.12 per share compare to $0.35 a year prior and earnings grew by 35.15 % from $0.09 per share from the preceding quarter.

Sales faded by -42.97 % to $2.05 millions from $3.59 millions in the same quarter a year prior and sequentially Sales surged by 75.31 % from $1.17 millions.

Atai Life Sciences N V

Shifting our awareness towards the most recent fiscal period the Educational Services company posted a shortfall per stock at $-4.20 per share, relative to the results of $0.61 per share a year prior quarter, In the previous quarter the Atai Life Sciences N V realized $-0.22 per share.

Mink Therapeutics Inc

The emerging corporation from the Biotechnology & Pharmaceuticals market the INKT reported the most recent fiscal period, numbers

While the earnings cycle of fiscal October to December 31 2022 season resumes, many companies have announced the results. Among them, are multiple constituents of the Biotechnology & Pharmaceuticals sector. As well as, today, INKT reported operating shortfall of $-7.889209 millions, for the fiscal three months ending December 31 2022.

Aeva Technologies Inc

Very steep Deterioration at AEVA during the fiscal fourth quarter of 2022

the Auto & Truck Parts company reported disastrous fiscal three months ending December 31 2022, where Sales faded by -93.456 % to $0.19 millions and net loss per share has widen to $-0.19, from the comparable quarter a year ago.


Edwards Lifesciences's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Edwards Lifesciences does not provide revenue guidance.

Earnings Outlook
Aeva Technologies Inc does not provide earnings estimates.

Geographic Revenue Dispersion


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

WDC's Profile

Stock Price

WDC's Financials

Business Description


Charts & Quotes

WDC's News


WDC's Competitors

Customers & Markets

Economic Indicators

WDC's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries




At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071